Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PALISADE BIO, INC. (CUR)
|
Add to portfolio |
|
|
|
| Price: |
$1.49
| | Metrics |
| OS: |
6.86
|
M
| |
-87
|
% ROE
|
| Market cap: |
$10.2
|
M
| |
-3869
|
% ROIC
|
|
Net cash:
|
$16
|
M
| |
$2.33
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($14.4)
|
M
| |
|
|
|
EBIT
|
($14.4)
|
M
| |
|
|
| EPS |
($5.71)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 10/05/2023 |
4
| Finley John David (CEO, CFO, Director) has filed a Form 4 on PALISADE BIO, INC. |
| 09/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/14/2023 |
4
| Finley John David (CEO, CFO, Director) has filed a Form 4 on PALISADE BIO, INC. |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/06/2023 |
4
| Finley John David (CEO, CFO, Director) has filed a Form 4 on PALISADE BIO, INC. |
| 06/09/2023 |
8-K
| Director compensation was amended/approved |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.3 | 0.0 | 0.0 |
| Revenue growth | | | -100.0% | -94.1% | 0.0% | 1500.4% | 56.0% | -44.7% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.3 | 0.0 | 0.0 |
| Gross margin | | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 6.5 | 2.4 | 3.1 | 4.1 | 4.0 | 8.1 | 13.2 | 12.6 |
| General and administrative | 8.8 | 9.3 | 6.2 | 4.6 | 4.6 | 5.5 | 7.5 | 6.5 |
| EBITA | -15.7 | -11.7 | -9.3 | -8.5 | -8.2 | -13.1 | -21.1 | -19.0 |
| EBITA margin | | | | -55454.7% | -3137.5% | -5045.4% | -130008.0% | -182005.6% |
| Amortization of intangibles | | | | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 |
| EBIT | -15.7 | -11.7 | -9.3 | -8.6 | -8.3 | -13.3 | -21.3 | -19.2 |
| EBIT margin | | | | -56071.8% | -3176.7% | -5118.1% | -131091.3% | -183896.8% |
| Pre-tax income | -14.3 | -26.6 | -10.3 | -8.4 | -4.9 | -15.7 | -21.1 | -20.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -14.5 | -31.7 | -10.3 | -8.4 | -4.9 | -15.7 | -21.1 | -20.9 |
| Net margin | | | | -54252.6% | -1894.1% | -6025.4% | -129721.8% | -200671.0% |
| |
| Diluted EPS | ($16.53) | ($169.74) | ($3.72) | ($3.80) | ($7.54) | ($1.20) | ($2.53) | ($2.99) |
| Shares outstanding (diluted) | 0.9 | 0.2 | 2.8 | 2.2 | 0.7 | 13.1 | 8.3 | 7.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|